Celastrol can reduce the activation of Notch-1 and the expression of HES-1 and HEY-1 of the downstream target protein and inhibit the stem cells of triple-negative breast cancer, thereby reducing the possibility of distant metastasis (Ramamoorthy et al., 2021). Here, HES1 is linked to triple-negative breast carcinoma.